Nano-Pharmacology: Nanotechnology Based Therapeutics for Targeting Neuroinflammation
A special issue of Immuno (ISSN 2673-5601). This special issue belongs to the section "Neuroimmunology".
Deadline for manuscript submissions: 31 August 2025 | Viewed by 46
Special Issue Editor
Interests: apoptosis and cell death; bioinformatics; endocrinology; gene expression; gene therapy; genomics and proteomics; immunology; molecular and cellular biology; molecular basis of disease; neurobiology; RNA; viral pathogenesis
Special Issue Information
Dear Colleagues,
Neuroimmunology is reshaping the understanding of the central nervous system (CNS). Neuroinflammation is a complex process that involves the activation of microglia, astrocytes, and other immune cells in the brain. Significant advances have been made in developing nano-formulations to target microglia, astrocytes, and other immune cells in the brain, thereby reducing neuroinflammation and protecting neurons from injury. The chapters in this Special Issue will cover translational studies in the field that highlight the role of microglia, astrocytes, and the blood–brain barrier (BBB) in orchestrating neuroimmune dynamics. Our Special Issue will focus on various nano-pharmacology aspects that involve using nanotechnology tools, such as novel drug carriers, which facilitate the selection of efficacious combinations of pharmaceuticals. Ultimately, their goal is centered around increasing therapeutic efficacy and reducing drug toxicity in the context of CNS disorders, such as drug addiction, Alzheimer’s disease, glioblastomas, traumatic brain injuries, and co-morbidities associated with HIV.
Dr. Supriya Mahajan
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Immuno is an international peer-reviewed open access quarterly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1000 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- nano-pharmacology
- nanotherapeutics
- neuroinflammation
- neuroimmunology
- blood–brain barrier (BBB)
- neurological diseases
- central nervous system (CNS)
- microglia/astrocytes/pericytes/brain microvascular endothelial cells
- neural cells
- dopaminergic neurons
- computational neuroscience
- neuroplasticity
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue policies can be found here.
